Scholarlink

Background <p>Unlike many other solid tumors, melanoma cells possess a remarkable ability to dynamically transition between distinct transcriptional states in response to environmental cues or therapeutic pressure. Among the adaptive mechanisms underlying this plasticity, the epithelial-to-mesenchymal transition (EMT) has garnered increasing attention, as it facilitates the shift from a proliferative, epithelial-like phenotype to a more invasive, mesenchymal-like phenotype frequently associated with cellular dormancy, quiescence and resistance to therapy. Despite growing interest in this phenomenon, the characterization of dormant cellular phenotypes and their clinical significance remains incomplete.</p> Methods <p>In this study, we adopted a comprehensive approach integrating patient-derived melanoma cell lines, bulk RNA sequencing from tumor biopsies and analysis of independent bulk and single-cell public datasets. This multi-dimensional strategy enabled the identification of a reproducible dichotomy between “proliferative” and “dormant” phenotypes, characterized by distinct levels of mitotic activity and mesenchymal gene expression profiles. By leveraging an eight-gene transcriptional signature, we constructed a “dormancy score” able to stratify tumors along a dormancy–proliferation axis, revealing strong associations with clinical outcomes such as progression-free survival (PFS), overall survival (OS) and response to immunotherapy.</p> Results <p>Within the dormant-associated gene module, the surface glycoprotein TACSTD2 (TROP2) emerged as a central hub gene. TROP2 expression was consistently upregulated in the dormant-like transcriptional state. Supporting these findings, single-cell RNA sequencing data confirmed that TROP2 marks a rare subpopulation of malignant cells that may constitute a quiescent, therapy-resistant niche. Besides, results highlight a predominant intracellular expression of TROP2 in the dormant phenotype.</p> Conclusions <p>Together, these findings define a robust dormant phenotype in melanoma with both molecular and clinical significance and evaluate TROP2 as a potential biomarker and therapeutic target for identifying and eradicating dormant and treatment-refractory tumor cells.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Biopsy RNA-seq captures TROP-2–linked migration and clonal resistance to forecast aggressiveness in metastatic melanoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月28日

查看全文
  • Martina Betti,
  • Celeste Accetta,
  • Brindusa Ana Maria Arteni,
  • Anya Rosselli,
  • Elisa Melucci,
  • Paolo Visca,
  • Claudio Botti,
  • Fabio Pelle,
  • Michelangelo Russillo,
  • Virginia Ferraresi,
  • Emilia Migliano,
  • Marianna Cerro,
  • Stefano Scalera,
  • Francesca De Nicola,
  • Silvia Matteoni,
  • Daniela Covino,
  • Antonino Guerrisi,
  • Matteo Pallocca,
  • Maurizio Fanciulli,
  • Edoardo Pescarmona,
  • Giovanni Blandino,
  • Rita Mancini,
  • Italia Falcone,
  • Simona Di Martino

摘要

Background

Unlike many other solid tumors, melanoma cells possess a remarkable ability to dynamically transition between distinct transcriptional states in response to environmental cues or therapeutic pressure. Among the adaptive mechanisms underlying this plasticity, the epithelial-to-mesenchymal transition (EMT) has garnered increasing attention, as it facilitates the shift from a proliferative, epithelial-like phenotype to a more invasive, mesenchymal-like phenotype frequently associated with cellular dormancy, quiescence and resistance to therapy. Despite growing interest in this phenomenon, the characterization of dormant cellular phenotypes and their clinical significance remains incomplete.

Methods

In this study, we adopted a comprehensive approach integrating patient-derived melanoma cell lines, bulk RNA sequencing from tumor biopsies and analysis of independent bulk and single-cell public datasets. This multi-dimensional strategy enabled the identification of a reproducible dichotomy between “proliferative” and “dormant” phenotypes, characterized by distinct levels of mitotic activity and mesenchymal gene expression profiles. By leveraging an eight-gene transcriptional signature, we constructed a “dormancy score” able to stratify tumors along a dormancy–proliferation axis, revealing strong associations with clinical outcomes such as progression-free survival (PFS), overall survival (OS) and response to immunotherapy.

Results

Within the dormant-associated gene module, the surface glycoprotein TACSTD2 (TROP2) emerged as a central hub gene. TROP2 expression was consistently upregulated in the dormant-like transcriptional state. Supporting these findings, single-cell RNA sequencing data confirmed that TROP2 marks a rare subpopulation of malignant cells that may constitute a quiescent, therapy-resistant niche. Besides, results highlight a predominant intracellular expression of TROP2 in the dormant phenotype.

Conclusions

Together, these findings define a robust dormant phenotype in melanoma with both molecular and clinical significance and evaluate TROP2 as a potential biomarker and therapeutic target for identifying and eradicating dormant and treatment-refractory tumor cells.